CN115348970B - 结合siglec15的抗体及其用途 - Google Patents

结合siglec15的抗体及其用途 Download PDF

Info

Publication number
CN115348970B
CN115348970B CN202180024369.4A CN202180024369A CN115348970B CN 115348970 B CN115348970 B CN 115348970B CN 202180024369 A CN202180024369 A CN 202180024369A CN 115348970 B CN115348970 B CN 115348970B
Authority
CN
China
Prior art keywords
ser
leu
val
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180024369.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115348970A (zh
Inventor
陈明久
夏树开
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boaoxin Biotechnology Nanjing Co ltd
Original Assignee
Boaoxin Biotechnology Nanjing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boaoxin Biotechnology Nanjing Co ltd filed Critical Boaoxin Biotechnology Nanjing Co ltd
Publication of CN115348970A publication Critical patent/CN115348970A/zh
Application granted granted Critical
Publication of CN115348970B publication Critical patent/CN115348970B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180024369.4A 2020-03-27 2021-03-26 结合siglec15的抗体及其用途 Active CN115348970B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000566P 2020-03-27 2020-03-27
US63/000,566 2020-03-27
PCT/CN2021/083194 WO2021190622A1 (en) 2020-03-27 2021-03-26 Antibodies binding siglec15 and uses thereof

Publications (2)

Publication Number Publication Date
CN115348970A CN115348970A (zh) 2022-11-15
CN115348970B true CN115348970B (zh) 2023-11-14

Family

ID=77891322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024369.4A Active CN115348970B (zh) 2020-03-27 2021-03-26 结合siglec15的抗体及其用途

Country Status (12)

Country Link
US (2) US11739147B2 (enExample)
EP (1) EP4126938A4 (enExample)
JP (2) JP7364315B2 (enExample)
KR (1) KR102651263B1 (enExample)
CN (1) CN115348970B (enExample)
AU (2) AU2021240769B2 (enExample)
BR (1) BR112022019129A2 (enExample)
IL (1) IL296736B2 (enExample)
MX (1) MX2022011951A (enExample)
PH (1) PH12022552520A1 (enExample)
SA (1) SA522440646B1 (enExample)
WO (1) WO2021190622A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011951A (es) * 2020-03-27 2023-03-06 Biosion Inc Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
CN118159286A (zh) * 2021-11-25 2024-06-07 正大天晴药业集团股份有限公司 抗Siglec-15抗体及其应用
CN114134183B (zh) * 2021-12-24 2022-12-06 广东南模生物科技有限公司 一种siglec15基因人源化动物模型的构建方法及应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
CN119403838A (zh) * 2022-06-13 2025-02-07 上海生物制品研究所有限责任公司 抗siglec15抗体及其用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108250296A (zh) * 2018-01-17 2018-07-06 长春金赛药业股份有限公司 全人源抗人pd-l1单克隆抗体及其应用
CN110035769A (zh) * 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2813314A1 (en) * 2010-10-05 2012-04-12 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
EP2753356B1 (en) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
JPWO2013147212A1 (ja) * 2012-03-30 2015-12-14 第一三共株式会社 新規抗Ｓｉｇｌｅｃ−１５抗体
AU2013293062A1 (en) * 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
US20170129956A1 (en) * 2014-06-18 2017-05-11 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
KR102810368B1 (ko) 2015-11-10 2025-05-19 예일 유니버시티 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
CN112638947B (zh) * 2018-08-30 2022-09-30 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
US11323026B2 (en) 2019-09-06 2022-05-03 Intel Corporation Hybrid digital linear and switched capacitor voltage regulator
MX2022011951A (es) * 2020-03-27 2023-03-06 Biosion Inc Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
US20250361297A1 (en) * 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110035769A (zh) * 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法
CN108250296A (zh) * 2018-01-17 2018-07-06 长春金赛药业股份有限公司 全人源抗人pd-l1单克隆抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The diverse functions of Siglec-15 in bone remodeling and antitumor responses.;Fu-Biao,Kang等;PHARMACOLOGICAL RESEARCH;155;第1-5页 *

Also Published As

Publication number Publication date
EP4126938A4 (en) 2024-04-10
AU2021240769B2 (en) 2023-04-06
IL296736A (en) 2022-11-01
BR112022019129A2 (pt) 2022-12-06
US20240002508A1 (en) 2024-01-04
CN115348970A (zh) 2022-11-15
IL296736B2 (en) 2025-04-01
JP2024016024A (ja) 2024-02-06
US12649789B2 (en) 2026-06-09
WO2021190622A1 (en) 2021-09-30
AU2023203397A1 (en) 2023-06-29
KR102651263B1 (ko) 2024-03-25
PH12022552520A1 (en) 2023-01-04
CA3173201A1 (en) 2021-09-30
AU2023203397B2 (en) 2026-05-21
KR20220158696A (ko) 2022-12-01
EP4126938A1 (en) 2023-02-08
NZ792658A (en) 2024-07-05
US11739147B2 (en) 2023-08-29
JP7827951B2 (ja) 2026-03-11
US20230106715A1 (en) 2023-04-06
MX2022011951A (es) 2023-03-06
SA522440646B1 (ar) 2024-08-29
AU2021240769A1 (en) 2022-10-20
JP2023518153A (ja) 2023-04-28
IL296736B1 (en) 2024-12-01
JP7364315B2 (ja) 2023-10-18

Similar Documents

Publication Publication Date Title
CN114981309B (zh) 结合bcma的抗体及其用途
CN113423733B (zh) 结合tslp的抗体及其用途
KR102651263B1 (ko) Siglec15에 결합하는 항체 및 이의 용도
CN115087673B (zh) 结合il4r的抗体及其用途
KR102673591B1 (ko) Pd-1에 결합하는 항체 및 그 용도
CN115297888A (zh) 结合cd40的抗体及其用途
WO2022222992A1 (en) Antibodies binding trop2 and uses thereof
CN112074533A (zh) 结合pd-1的抗体及其用途
CN115667297B (zh) 结合il6r的抗体及其用途
CN115443291B (zh) 结合ctla4的抗体及其用途
RU2839071C1 (ru) Антитела, связывающие siglec15, и варианты их применения
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
RU2773758C2 (ru) Связывающиеся с pd-1 антитела и способы их применения
CN114829392B (zh) 结合rankl的抗体及其用途
HK40058295A (en) Antibodies binding tslp and uses thereof
HK40058295B (en) Antibodies binding tslp and uses thereof
HK40079597A (en) Antibodies binding il4r and uses thereof
HK40033442A (en) Antibodies binding pd-1 and uses thereof
HK40033442B (en) Antibodies binding pd-1 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant